FDA To Review Whether To Allow More Access To Certain Peptides

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 17, 2026.

via HealthDay

FRIDAY, April 17, 2026 — The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.

Peptides are small chains of amino acids that are marketed for a wide range of uses, including treating wounds, obesity, insomnia and inflammatory conditions.

An FDA advisory panel is set to meet in late July, a notice posted earlier this week shows, to discuss seven peptides now restricted due to safety concerns.

The compounds have been promoted for their health and antiaging benefits, and Health Secretary Robert F. Kennedy Jr. has voiced his support for expanding access to them.

“This action begins to restore regulated access and will immediately begin shifting demand away from the black market,” he wrote in a social media post.

Peptides are already used in some approved medicines, such as insulin and certain weight loss drugs.

But many newer peptide products, like injectable forms sold online, have not gone through clinical trials to confirm they are safe.

The FDA placed several peptides into a limited category in 2023, meaning they should not be used in compounded drugs due to potential risks, The Washington Post reported.

Still, some telehealth companies and social media influencers promote combinations of these peptides, even though there is little research on how these mixtures work.

"Compounding pharmacies are being hammered by patients and prescribers to prepare these peptide drugs, and legally, they can’t do it. Not yet, anyway," Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, a trade group, told The Post.

"And that is stimulating the illicit, non-pharmacy actors in the gray market," he added.

The FDA will also review five additional peptides by early 2027, The Post said.

Some scientists are hesitant, however.

“There’s just so little data that it’s hard to even put your finger on all the possible risks,” Paul Knoepfler, a professor at the University of California at Davis School of Medicine, told The Post.

Sources

  • The Washington Post, April 15, 2026
  • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords